Claris Lifesciences shares rose nearly 6 per cent after the company received approval from the US health regulator for generic Tobramycin injection used for the treatment of bacterial infections, in the American market.
The stock climbed 5.59 per cent to settle at Rs 229.35 on BSE. During the day, it gained 13.28 per cent to Rs 246.05.
The company's market valuation rose by Rs 66.51 crore to Rs 1,251.51 crore.
"The company has received abbreviated new drug application (ANDA) approval from the United States Food and Drug Administration (USFDA) for Tobramycin injection USP, 80 mg/2 mL and 1,200 mg/30 mL multiple dose vials," Claris Lifesciences had said in a BSE filing yesterday.
The estimated market size of the product in the US is USD 6 million. The product is currently in the shortage list of the USFDA, it added.
With this, the company has a total of 14 approvals and 24 under approval ANDAs and is expecting more product approvals during the year, Claris Lifesciences said.
